GWM
XGN icon

Geneos Wealth Management’s Exagen XGN Stock Holding History

Geneos Wealth Management’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.65K Buy
+1,000
New +$3.77K ﹤0.01% 2203

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Geneos Wealth Management's XGN Position: Q2 2026 in Review

Geneos Wealth Management opened a new position in Exagen (XGN) in Q2 2026: 1,000 shares worth $4.65K. The stake represents ﹤0.01% of the portfolio and ranks #2203 among its holdings.

57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • Geneos Wealth Management held 1,000 shares of Exagen worth $4.65K as of Q2 2026.
  • Exagen was a new Geneos Wealth Management position in Q2 2026.
  • Exagen made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #2203 holding.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.